IDEAYA Biosciences (IDYA) Interest Expenses (2018 - 2026)
IDEAYA Biosciences (IDYA) posted Interest Expenses of $121.5 million for Q1 2026, up 40586.67% sequentially from -$300000.0 in Q4 2025, and up 1175.84% YoY from $9.5 million in Q1 2025.
IDEAYA Biosciences (IDYA) Interest Expenses (2018 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Interest Expenses for 9 years, with the latest figure at $121.5 million in Q1 2026.
- Quarterly Interest Expenses rose 1175.84% year-over-year to $121.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $121.5 million (up 1175.84% YoY) and the FY2025 annual result came in at $196.4 million, up 19.12% from the prior year.
- Interest Expenses grew to $121.5 million in Q1 2026 per IDYA's latest filing, from -$300000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $121.5 million in Q1 2026 and troughed at -$1.4 million in Q4 2023.
- A 5-year average of $29.4 million and a median of $9.3 million in 2022 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses jumped 91150.0% in 2022, then tumbled 10321.43% in 2023.
- Over 5 years, Interest Expenses stood at $14000.0 in 2022, then sank by 10321.43% to -$1.4 million in 2023, then jumped by 5178.97% to $72.7 million in 2024, then tumbled by 100.41% to -$300000.0 in 2025, then soared by 40586.67% to $121.5 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $121.5 million, -$300000.0, and $78.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | 166.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 166.01 Mn |
| Jun 30, 2026 | 166.01 Mn |
| Mar 31, 2026 | 121.46 Mn |
| Mar 31, 2026 | 121.46 Mn |
| Dec 31, 2025 | -300,000.00 |
| Dec 31, 2025 | -300,000.00 |
| Sep 30, 2025 | 78.83 Mn |
| Sep 30, 2025 | 78.83 Mn |
| Jun 30, 2025 | 46.55 Mn |
| Jun 30, 2025 | 46.55 Mn |
| Mar 31, 2025 | 9.52 Mn |
| Mar 31, 2025 | 9.52 Mn |
| Sep 30, 2024 | 72.68 Mn |
| Sep 30, 2024 | 72.68 Mn |
| Jun 30, 2024 | 96.02 Mn |
| Jun 30, 2024 | 96.02 Mn |
| Mar 31, 2024 | 1.04 Mn |
| Mar 31, 2024 | 1.04 Mn |
| Dec 31, 2023 | -1.43 Mn |
| Dec 31, 2023 | -1.43 Mn |